Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 2, 2008, Pages 158-162

  Bacharier, Leonard B ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Asthma; Inhaled corticosteroids; Leukotriene receptor antagonists; Preschool children

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE CHLOROFLUOROCARBON; FLUTICASONE PROPIONATE HYDROFLUOROALKANE; GLUCOCORTICOID; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO;

ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CELL MIGRATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG FUNCTION; MUCUS SECRETION; PRIORITY JOURNAL; REVIEW; THRUSH; URINARY EXCRETION; WHEEZING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ASTHMA; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; LEUKOTRIENE ANTAGONISTS; TREATMENT OUTCOME;

EID: 43249112735     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f64802     Document Type: Review

References (26)

1. Martinez F, Wright A, Taussig L, et al. Asthma and wheezing in the first six years of life. N Engl J Med 1995; 332:133-138.
2. Yunginger J, Reed C, O'Connell E, et al. A community-based study of the epidemiology of asthma. Am Rev Respir Dis 1992; 146:888-894.
3. Centers for Disease Control and Prevention. National Surveillance for Asthma: United States, 1980-2004. MMWR Surveillance Summaries 2007; 56:1-54. Updated statistics reflect the multiple elements of asthma burden in the United States.
4. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83:231-239.
5. Baker J, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103:414-421.
6. Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113:e87-e94.
7. Carlsen KC, Stick S, Kamin W, et al. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Respir Med 2005; 99:1393-1402.
8. Wasserman RL, Baker JW, Kim KT, et al. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2006; 96:808-818. A double-blind placebo-controlled trial demonstrated efficacy of fluticasone propionate relative to placebo in 2-4-year old children with asthma.
9. Qaqundah PY, Sugerman RW, Ceruti E, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in preschool-age children with asthma: A randomized, double-blind, placebo-controlled study. J Pediatr 2006; 149:663-670. A well controlled study demonstrated efficacy of fluticasone propionate HFA relative to placebo in 1-4-year-old children with asthma.
10. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997. This trial was primarily designed to assess the capacity of inhaled corticosteroids to alter the natural course of early childhood wheezing in young children at high risk for asthma. While ICS therapy was not effective in altering the natural course of asthma, twice daily ICS therapy was associated with significant improvements in multiple aspects of asthma symptom burden.
11. Teper AM, Kofman CD, Szulman GA, et al. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med 2005; 171:587-590.
12. Hofhuis W, van der Wiel EC, Nieuwhof EM, et al. Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants. Am J Respir Crit Care Med 2005; 171:328-333.
13. Moeller A, Franklin P, Hall GL, et al. Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrenty wheezy infants. Pediatr Pulmonol 2004; 38:250-255.
14. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.
15. Bisgaard H. Montelukast for viral respiratory infection-induced exacerbations of asthma. Am J Respir Crit Care Med 2005; 172:783-784.
16. Robertson CF, Price D, Henry R, et al. Short course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175:323-329. Episodic use of montelukast during times of increased symptoms or upper respiratory tract infections was associated with modest improvements in health-care utilization and symptom scores during acute respiratory illnesses.
17. Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120:e702-e712. Montelukast added to usual asthma therapy during the September 'epidemic' was associated with reductions in days with worsening asthma symptoms and unscheduled office visits.
18. Hakim F, Vilozni D, Adler A, et al. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007; 131:180-186. Montelukast therapy for 4 weeks was associated with a significant improvement in bronchial hyperresponsiveness to methacholine relative to placebo.
19. Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25:289-294.
20. Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2-5 years old. Chest 2005; 127:509-514.
21. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
22. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45-52.
23. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360-369.
24. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147:213-220.
25. Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64-72.
26. Szefler S, Baker JW, Uryniak MS, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120:1043-1050. This describes the first trial examining the efficacy of ICS and LTRA head-to-head in preschool children with asthma.